RENOVARO INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.53 USD | -10.00% |
|
-29.49% | -51.74% |
| 04-24 | Renovaro's RenovaroCube Amends Agreement to Acquire 100% Stake in Cyclomics | MT |
| 04-18 | Renovaro Inc. Announces Geert Kazemier, MD, PhD, as the New Chairman of its Scientific Advisory Board | CI |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 34.41M 2.75B |
|---|---|---|---|---|---|
| Net income 2022 | -113M -9.05B | Net income 2023 | -39M -3.12B | EV / Sales 2022 | - |
| Net cash position 2022 | 1.99M 159M | Net Debt 2023 | 3.9M 313M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-0.89
x | P/E ratio 2023 |
-0.8
x | Employees | 12 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 73.77% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -10.00% | ||
| 1 week | -29.49% | ||
| Current month | -42.26% | ||
| 1 month | -47.60% | ||
| 3 months | -67.10% | ||
| 6 months | -45.36% | ||
| Current year | -51.74% |
1 week
1.50
2.20
1 month
1.503.05
Current year
1.505.25
1 year
0.395.25
3 years
0.3913.78
5 years
0.3913.78
10 years
0.3913.78
| Managers | Title | Age | Since |
|---|---|---|---|
Mark Dybul
CEO | Chief Executive Officer | 60 | 22/01/18 |
Lester Russell
CTO | Chief Tech/Sci/R&D Officer | - | 20/08/23 |
Greg Duczynski
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gregg Alton
BRD | Director/Board Member | 58 | 31/12/19 |
Avram Miller
BRD | Director/Board Member | - | 10/10/23 |
James Sapirstein
BRD | Director/Board Member | 63 | 05/03/18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 18 M€ | +3.86% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 1.53 | -10.00% | 1,044,301 |
| 25/04/24 | 1.7 | -13.71% | 428,027 |
| 24/04/24 | 1.97 | -2.48% | 206,935 |
| 23/04/24 | 2.02 | -6.05% | 292,628 |
| 22/04/24 | 2.15 | -0.92% | 110,931 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Renovaro Inc., formerly Renovaro BioSciences Inc., is a biotechnology company. The Company is engaged in the research and development of pharmaceutical and biological products for the treatment of cancer, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. The Company has a single product candidate as a potential cure for HIV, RENB-HV01, adding two additional pipeline candidates for HIV, RENB-HV12 and RENB-HV21, a pipeline for HBV, RENB-HB01, and with a significant into cancer immune therapies to address high unmet needs from difficult-to-treat solid tumors, RENB-DC11. RENB-HV-01 is a HIV autologous transplant with genetically modified cells. RENB-HV12 is a HIV therapeutic vaccine for potential long-term remission/cure. RENB-HV-21, a treatment for HIV with allogenic Natural Killer (NK) and Gamma Delta T-Cells (GDT). RENB-HB-01 is an HBV gene therapy candidate.
| 1st Jan change | Capi. | |
|---|---|---|
| -51.74% | 220M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- RENB Stock
